O
Osman H. Yilmaz
Researcher at Boston University
Publications - 7
Citations - 3125
Osman H. Yilmaz is an academic researcher from Boston University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 2931 citations. Previous affiliations of Osman H. Yilmaz include University of Michigan.
Papers
More filters
Journal ArticleDOI
SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells
Mark J. Kiel,Ömer H. Yilmaz,Toshihide Iwashita,Osman H. Yilmaz,Cox Terhorst,Sean J. Morrison +5 more
TL;DR: This work compared the gene expression profiles of highly purified HSCs and non-self-renewing multipotent hematopoietic progenitors and found that both groups occupied multiple niches, including sinusoidal endothelium in diverse tissues.
Journal ArticleDOI
TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas
Noah A. Brown,Komal R. Plouffe,Osman H. Yilmaz,Steven C. Weindorf,Bryan L. Betz,Thomas E. Carey,Raja R. Seethala,Jonathan B. McHugh,Scott A. Tomlins,Aaron M. Udager +9 more
TL;DR: Compared to aerodigestive tract squamous cell carcinomas from The Cancer Genome Atlas (TCGA) project, sinonasal papilloma-associated sin onasal carcinomas have a distinct molecular phenotype, including more frequent EGFR, KRAS, and CDKN2A mutations, TERT copy-number gains, and low-risk human papillomavirus (HPV) infection.
Journal ArticleDOI
Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Epidemiology and Long-Term Outcomes in a Strictly Defined Cohort
Rainjade Chung,Rainjade Chung,Haixia Guan,Haixia Guan,Cecilia Ponchiardi,Sandra Cerda,Nitin Marwaha,Osman H. Yilmaz,Emma Pinjic,David McAneny,Stephanie L. Lee,Frederick Thurston Drake +11 more
TL;DR: The NIFTP re-classification may substantially reduce the number of patients who require adjuvant therapies, such as completion surgery or RAI, in a high-volume, urban, tertiary referral center.
Journal ArticleDOI
Programmed death-ligand 1 expression in the immune compartment of colon carcinoma
Osman H. Yilmaz,Amaya Pankaj,Azfar Neyez,Steffen Rickelt,Martin S. Taylor,Evan R. Lang,Lieve Leijsen,Anne M. Dinaux,Stuti Shroff,Rory Crotty,M. Lisa Zhang,Sandra Cerda,Qing Zhao,Cristina R. Ferrone,David Ring,Deepa T. Patil,Omer Hidir Yilmaz,David Berger,Vikram Deshpande +18 more
TL;DR: Resected colonic carcinomas with high expression of PD-L1 and LAG3 proteins on immune cells were associated with improved prognosis in colon carcinoma and the mechanism underlying theImproved prognosis of colon carcinomas bearing high numbers of immunoregulatory cells needs further investigation.
Posted ContentDOI
Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker
Martin S. Taylor,Connie Wu,Peter C. Fridy,Stephanie J. Zhang,Y. Senussi,Justina C. Wolters,Wen-Chih Cheng,John Heaps,Bryant D. Miller,Kei Mori,Limor Cohen,Hua Jiang,Kelly R. Molloy,Brian T. Chait,Michael Goggins,Irun Bhan,Joseph W. Franses,Xiaoyu Yang,Mary-Ellen Taplin,Xinan Wang,David C. Christiani,Bruce E. Johnson,Matthew Meyerson,Ravindra Uppaluri,Ann Marie Egloff,Elyssa N. Denault,Laura Spring,Tian Li Wang,Ie Ming Shih,Euihye Jung,Kshitij S. Arora,Lawrence R. Zukerberg,Osman H. Yilmaz,Gary Chi,Bryanna L. Norden,Yuhui Song,Linda T. Nieman,Aparna Raj Parikh,Matthew Strickland,Ryan B. Corcoran,Tomas Mustelin,George Eng,Ömer H. Yilmaz,Ursula A. Matulonis,Steven J. Skates,Bo R. Rueda,Ronny Drapkin,Samuel J. Klempner,Vikram Deshpande,David Ring,Michael P. Rout,John LaCava,David R. Walt,Kathleen H. Burns +53 more
TL;DR: In this paper , the authors explored the potential of ORF1p as a blood-based biomarker for early cancer detection, risk stratification, treatment selection, and monitoring treatment response.